Skip to main content
Erschienen in: Endocrine Pathology 2/2021

17.04.2021

Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors

verfasst von: Sylvia L. Asa

Erschienen in: Endocrine Pathology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Detailed analysis of cytodifferentiation and hormone production has classified pituitary neuroendocrine tumors (PitNETs) in a formal system that reflects the lineage differentiation of nontumorous adenohypophysial cells as well as subtypes of tumors that have predictive value. In addition, tumors composed of cells that lack terminal differentiation are well characterized. To comply with the proposal to create an overarching classification of neuroendocrine neoplasia, these tumors are now called PitNETs rather than adenomas. The next important step will be to relinquish the term “pituitary carcinoma” for metastatic PitNETs that remain well differentiated, and to alter the terminology used for tumors that are not terminally differentiated to reflect only their immature lineage. The existence of mixed neuroendocrine and non-neuroendocrine neoplasms (MiNENs) similar to those at other body sites is proven by mixed craniopharyngiomas with PitNETs. As with other NETs, these neoplasms should be reported with synoptic data that guide completeness of reporting. A formal system of grading should be created, but not only based on proliferation, as these tumors have shown the prognostic value of cytodifferentiation. A formal system of staging should also be devised to complement grade in the thorough and accurate diagnosis of tumors that arise from adenohypophysial cells.
Literatur
1.
Zurück zum Zitat Asa SL, Perry A. Tumors of the Pituitary Gland. AFIP Atlas of Tumor and Nontumor Pathology, Series 5, Fascicle 1. Arlington VA: ARP Press; 2020. Asa SL, Perry A. Tumors of the Pituitary Gland. AFIP Atlas of Tumor and Nontumor Pathology, Series 5, Fascicle 1. Arlington VA: ARP Press; 2020.
2.
Zurück zum Zitat Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770-86.PubMedPubMedCentralCrossRef Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770-86.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017;24:C5-C8.PubMedCrossRef Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017;24:C5-C8.PubMedCrossRef
4.
Zurück zum Zitat Asa S.L., Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, et al. Pituitary Neuroendocrine Tumors: A Model for Neuroendocrine Tumor Classification. Mod Pathol 2021, in press. Asa S.L., Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, et al. Pituitary Neuroendocrine Tumors: A Model for Neuroendocrine Tumor Classification. Mod Pathol 2021, in press.
5.
Zurück zum Zitat Asa SL, Mete O, Ezzat S. Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know? Endocr Pathol 2021;32:3-16.PubMedCrossRef Asa SL, Mete O, Ezzat S. Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know? Endocr Pathol 2021;32:3-16.PubMedCrossRef
6.
Zurück zum Zitat Casar-Borota O, Boldt HB, Engstrom BE, Andersen MS, Baussart B, Bengtsson D, et al. Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations. J Clin Endocrinol Metab 2020. Casar-Borota O, Boldt HB, Engstrom BE, Andersen MS, Baussart B, Bengtsson D, et al. Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations. J Clin Endocrinol Metab 2020.
7.
Zurück zum Zitat Alshaikh OM, Asa SL, Mete O, Ezzat S. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. Endocr Pathol 2019;30:118-27.PubMedCrossRef Alshaikh OM, Asa SL, Mete O, Ezzat S. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. Endocr Pathol 2019;30:118-27.PubMedCrossRef
8.
Zurück zum Zitat McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 2018;178:265-76.PubMedCrossRef McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 2018;178:265-76.PubMedCrossRef
9.
Zurück zum Zitat Lenders N, McCormack A. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). Pituitary 2018;21:217-29.PubMedCrossRef Lenders N, McCormack A. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). Pituitary 2018;21:217-29.PubMedCrossRef
10.
Zurück zum Zitat Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 2018;178:G1-G24.PubMedCrossRef Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 2018;178:G1-G24.PubMedCrossRef
11.
Zurück zum Zitat Kawashima ST, Usui T, Sano T, Iogawa H, Hagiwara H, Tamanaha T, et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease. Clin Endocrinol (Oxf) 2009;70:656-7.CrossRef Kawashima ST, Usui T, Sano T, Iogawa H, Hagiwara H, Tamanaha T, et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease. Clin Endocrinol (Oxf) 2009;70:656-7.CrossRef
12.
Zurück zum Zitat Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV. P53 gene mutations in pituitary carcinomas. Endocr Pathol 2007;18:217-22.PubMedCrossRef Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV. P53 gene mutations in pituitary carcinomas. Endocr Pathol 2007;18:217-22.PubMedCrossRef
13.
Zurück zum Zitat Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-71.PubMedCrossRef Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-71.PubMedCrossRef
14.
Zurück zum Zitat Levy A, Hall L, Yeundall WA, Lightman SL. p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol (Oxf) 1994;41:809-14.CrossRef Levy A, Hall L, Yeundall WA, Lightman SL. p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol (Oxf) 1994;41:809-14.CrossRef
15.
Zurück zum Zitat Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in USP8 wild type Cushing's disease. Neuro Oncol 2019. Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in USP8 wild type Cushing's disease. Neuro Oncol 2019.
16.
Zurück zum Zitat Finzi G, Cerati M, Marando A, Zoia C, Ferreli F, Tomei G, et al. Mixed pituitary adenoma/craniopharyngioma: clinical, morphological, immunohistochemical and ultrastructural study of a case, review of the literature, and pathogenetic and nosological considerations. Pituitary 2014;17:53-9.PubMedCrossRef Finzi G, Cerati M, Marando A, Zoia C, Ferreli F, Tomei G, et al. Mixed pituitary adenoma/craniopharyngioma: clinical, morphological, immunohistochemical and ultrastructural study of a case, review of the literature, and pathogenetic and nosological considerations. Pituitary 2014;17:53-9.PubMedCrossRef
17.
Zurück zum Zitat Moshkin O, Scheithauer BW, Syro LV, Velasquez A, Horvath E, Kovacs K. Collision tumors of the sella: craniopharyngioma and silent pituitary adenoma subtype 3: case report. Endocr Pathol 2009;20:50-5.PubMedCrossRef Moshkin O, Scheithauer BW, Syro LV, Velasquez A, Horvath E, Kovacs K. Collision tumors of the sella: craniopharyngioma and silent pituitary adenoma subtype 3: case report. Endocr Pathol 2009;20:50-5.PubMedCrossRef
18.
Zurück zum Zitat Gokden M, Mrak RE. Pituitary adenoma with craniopharyngioma component. Hum Pathol 2009;40:1189-93.PubMedCrossRef Gokden M, Mrak RE. Pituitary adenoma with craniopharyngioma component. Hum Pathol 2009;40:1189-93.PubMedCrossRef
19.
Zurück zum Zitat Yoshida A, Sen C, Asa SL, Rosenblum MK. Composite pituitary adenoma and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation. Am J Surg Pathol 2008;32:1736-41.PubMedCrossRef Yoshida A, Sen C, Asa SL, Rosenblum MK. Composite pituitary adenoma and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation. Am J Surg Pathol 2008;32:1736-41.PubMedCrossRef
20.
Zurück zum Zitat Scully KM, Rosenfeld MG. Pituitary development: regulatory codes in mammalian organogenesis. Science 2002;295:2231-5.PubMedCrossRef Scully KM, Rosenfeld MG. Pituitary development: regulatory codes in mammalian organogenesis. Science 2002;295:2231-5.PubMedCrossRef
21.
Zurück zum Zitat Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998;19:798-827.PubMed Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998;19:798-827.PubMed
22.
Zurück zum Zitat Horvath E, Lloyd RV, Kovacs K. Propylthiouracyl-induced hypothyroidism results in reversible transdifferentiation of somatotrophs into thyroidectomy cells. A morphologic study of the rat pituitary including immunoelectron microscopy. Lab Invest 1990;63:511–20. Horvath E, Lloyd RV, Kovacs K. Propylthiouracyl-induced hypothyroidism results in reversible transdifferentiation of somatotrophs into thyroidectomy cells. A morphologic study of the rat pituitary including immunoelectron microscopy. Lab Invest 1990;63:511–20.
23.
Zurück zum Zitat Gomez-Hernandez K, Ezzat S, Asa SL, Mete O. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. Turk Patoloji Derg 2015;31 Suppl 1:4-17.PubMed Gomez-Hernandez K, Ezzat S, Asa SL, Mete O. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. Turk Patoloji Derg 2015;31 Suppl 1:4-17.PubMed
24.
Zurück zum Zitat Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 2016;29:131-42.PubMedCrossRef Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 2016;29:131-42.PubMedCrossRef
25.
Zurück zum Zitat Huang C, Ezzat S, Asa SL, Hamilton J. Dopaminergic resistant prolactinomas in the peripubertal population. J Pediatr Endocrinol Metab 2006;19:951-3.PubMedCrossRef Huang C, Ezzat S, Asa SL, Hamilton J. Dopaminergic resistant prolactinomas in the peripubertal population. J Pediatr Endocrinol Metab 2006;19:951-3.PubMedCrossRef
26.
Zurück zum Zitat Papathomas TG, Gaal J, Corssmit EP, Oudijk L, Korpershoek E, Heimdal K, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 2014;170:1-12.PubMedCrossRef Papathomas TG, Gaal J, Corssmit EP, Oudijk L, Korpershoek E, Heimdal K, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 2014;170:1-12.PubMedCrossRef
27.
Zurück zum Zitat Kovacs K, Horvath E, Ryan N, Ezrin C. Null cell adenoma of the human pituitary. Virchows Arch [Pathol Anat ] 1980;387:165-74.CrossRef Kovacs K, Horvath E, Ryan N, Ezrin C. Null cell adenoma of the human pituitary. Virchows Arch [Pathol Anat ] 1980;387:165-74.CrossRef
28.
Zurück zum Zitat Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018;31:900-9.PubMedCrossRef Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018;31:900-9.PubMedCrossRef
29.
Zurück zum Zitat Mete O, Asa SL. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocr Pathol 2020;31:330-6.PubMedCrossRef Mete O, Asa SL. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocr Pathol 2020;31:330-6.PubMedCrossRef
30.
Zurück zum Zitat Asa SL, Gerrie BM, Kovacs K, Horvath E, Singer W, Killinger DW, et al. Structure-function correlations of human pituitary gonadotroph adenomas in vitro. Lab Invest 1988;58:403-10.PubMed Asa SL, Gerrie BM, Kovacs K, Horvath E, Singer W, Killinger DW, et al. Structure-function correlations of human pituitary gonadotroph adenomas in vitro. Lab Invest 1988;58:403-10.PubMed
31.
Zurück zum Zitat Asa SL, Gerrie BM, Singer W, Horvath E, Kovacs K, Smyth HS. Gonadotropin secretion in vitro by human pituitary null cell adenomas and oncocytomas. J Clin Endocrinol Metab 1986;62:1011-9.PubMedCrossRef Asa SL, Gerrie BM, Singer W, Horvath E, Kovacs K, Smyth HS. Gonadotropin secretion in vitro by human pituitary null cell adenomas and oncocytomas. J Clin Endocrinol Metab 1986;62:1011-9.PubMedCrossRef
32.
Zurück zum Zitat Asa SL, Bamberger A-M, Cao B, Wong M, Parker KL, Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 1996;81:2165-70.PubMed Asa SL, Bamberger A-M, Cao B, Wong M, Parker KL, Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 1996;81:2165-70.PubMed
33.
Zurück zum Zitat Mete O, Kefeli M, Caliskan S, Asa SL. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mod Pathol 2019;32:484-9.PubMedCrossRef Mete O, Kefeli M, Caliskan S, Asa SL. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mod Pathol 2019;32:484-9.PubMedCrossRef
34.
Zurück zum Zitat Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol 2015;26:349-55.PubMedCrossRef Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol 2015;26:349-55.PubMedCrossRef
35.
Zurück zum Zitat Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med 2018;7. Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med 2018;7.
36.
Zurück zum Zitat Asa SL, Mete O. Cytokeratin profiles in pituitary neuroendocrine tumors. Hum Pathol 2021;107:87-95.PubMedCrossRef Asa SL, Mete O. Cytokeratin profiles in pituitary neuroendocrine tumors. Hum Pathol 2021;107:87-95.PubMedCrossRef
37.
Zurück zum Zitat Mete O, Lopes MB, Asa SL. Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma. Am J Surg Pathol 2013;37:1694-9.PubMedCrossRef Mete O, Lopes MB, Asa SL. Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma. Am J Surg Pathol 2013;37:1694-9.PubMedCrossRef
38.
Zurück zum Zitat Asa SL, Ezzat S, Kelly DF, Cohan P, Takasumi Y, Barkhoudarian G, et al. Hypothalamic Vasopressin-producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease. Am J Surg Pathol 2018;42:251-60. Asa SL, Ezzat S, Kelly DF, Cohan P, Takasumi Y, Barkhoudarian G, et al. Hypothalamic Vasopressin-producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease. Am J Surg Pathol 2018;42:251-60.
39.
Zurück zum Zitat Asa SL. Survival Guide to Endocrine Pathology. Virginia: Innovative Pathology Press; 2020. Asa SL. Survival Guide to Endocrine Pathology. Virginia: Innovative Pathology Press; 2020.
40.
Zurück zum Zitat Mete O, Alshaikh OM, Cintosun A, Ezzat S, Asa SL. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. Endocr Pathol 2018;29:332-8.PubMedCrossRef Mete O, Alshaikh OM, Cintosun A, Ezzat S, Asa SL. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. Endocr Pathol 2018;29:332-8.PubMedCrossRef
41.
Zurück zum Zitat Nose V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R, et al. Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 2011;135:640-6.PubMedCrossRef Nose V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R, et al. Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 2011;135:640-6.PubMedCrossRef
42.
Zurück zum Zitat Asa SL, Ezzat S. Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. Expert Reviews Endocrinology and Metabolism 2016;11:149-62.CrossRef Asa SL, Ezzat S. Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. Expert Reviews Endocrinology and Metabolism 2016;11:149-62.CrossRef
43.
Zurück zum Zitat Hardy J. Transsphenoidal microsurgery of prolactinomas. In: Black PM, Zervas N, Ridgeway EC, et al., editors. Secretory Tumors of the Pituitary Gland.New York: Raven Press; 1984. p. 73-81. Hardy J. Transsphenoidal microsurgery of prolactinomas. In: Black PM, Zervas N, Ridgeway EC, et al., editors. Secretory Tumors of the Pituitary Gland.New York: Raven Press; 1984. p. 73-81.
44.
Zurück zum Zitat Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993;33:610-7. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993;33:610-7.
45.
Zurück zum Zitat Micko AS, Wohrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 2015;122:803-11.CrossRef Micko AS, Wohrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 2015;122:803-11.CrossRef
46.
Zurück zum Zitat Raverot G, Vasiljevic A, Jouanneau E, Trouillas J. A prognostic clinicopathologic classification of pituitary endocrine tumors. Endocrinol Metab Clin North Am 2015;44:11-8.PubMedCrossRef Raverot G, Vasiljevic A, Jouanneau E, Trouillas J. A prognostic clinicopathologic classification of pituitary endocrine tumors. Endocrinol Metab Clin North Am 2015;44:11-8.PubMedCrossRef
47.
Zurück zum Zitat Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013;126:123-35.PubMedCrossRef Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013;126:123-35.PubMedCrossRef
Metadaten
Titel
Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors
verfasst von
Sylvia L. Asa
Publikationsdatum
17.04.2021
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 2/2021
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-021-09678-x

Weitere Artikel der Ausgabe 2/2021

Endocrine Pathology 2/2021 Zur Ausgabe

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Thiopental Originalie

Als Folge des Urteils des Bundesverfassungsgerichts zur Sterbehilfe im Jahr 2020 wurde in den Jahren 2021–2023 eine Reihe (n = 23) von assistierten Suiziden im Landesinstitut für gerichtliche und soziale Medizin Berlin mit jeweils identischen …

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …